Marker Wins $2.6M FDA Orphan Grant for MT-601 Pancreatic Cancer Study
MRKR sits 31% above its 52-week low of $0.84 on elevated volume (13× avg).
Summary
Marker Therapeutics received a $2.6 million non-dilutive FDA Orphan Products grant to fund a Phase 1 study of MT-601 in pancreatic cancer, with clinical initiation targeted for Q1 2027.
Key Events · Product Development and Regulatory · MRKR
-
FDA Awards $2.6M Orphan Grant
Marker was selected as one of six recipients from 66 applications in the FDA's fiscal 2026 Orphan Products Clinical Trials grants cycle.
-
Funds MT-601 Pancreatic Study
The grant supports a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer and is non-dilutive, adding to existing NCI, CPRIT and SBIR support.
-
Clinical Start Targeted Q1 2027
Marker expects to begin its company-sponsored pancreatic cancer study in the first quarter of 2027; no trial has started yet.
-
Prior Baylor Data Cited
The program builds on a Baylor Phase 1/2 published in Nature Medicine showing an 84.6% disease control rate, 7.5-month median duration of response and 14.1-month median overall survival.
Analysis · MRKR · Life Sciences
Why it matters: Marker has secured $2.6 million in non-dilutive FDA funding for its lead MAR-T candidate, MT-601, in pancreatic cancer — one of only six projects funded out of 66 applications. For a company this small, that is meaningful, offsetting cash burn without issuing shares and arriving against a backdrop of going-concern doubt disclosed in the August 10-Q. The grant itself does not change the clinical risk: the company-sponsored study is not expected to start until Q1 2027, and the encouraging 84.6% disease control rate cited comes from a prior Baylor-run Phase 1/2, not from Marker's own trial.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRKR was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.3M. The 52-week trading range was $0.84 to $2.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.